These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3961894)

  • 21. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of blood coagulation in open heart surgery. II. Use of individualized dosages of heparin and protamine controlled by activated coagulation times.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):121-8. PubMed ID: 7468138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of a first-order model for estimating initial heparin dosage.
    Joch LE; Lutomski DM; Williams DJ; Bottorff M
    Clin Pharm; 1993 Aug; 12(8):597-601. PubMed ID: 8222524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of blood coagulation in open heart surgery. I. Effects of conventional dosages of heparin and protamine.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):113-9. PubMed ID: 7468137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
    Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodialysis without heparin infusion using Cordis Dow 3500 hollow fiber.
    Raja R; Kramer M; Rosenbaum JL; Bolisay C; Krug M
    Proc Clin Dial Transplant Forum; 1980; 10():39-42. PubMed ID: 7346852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of dialyzer geometry on blood coagulation and biocompatibility.
    Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R
    Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thromboxane B2 blood levels and incipient system clotting in heparin free hemodialysis.
    Keller F; Hericks K; Schuller I; Passfall J; Joerres A; Meinhold H
    ASAIO J; 1995; 41(2):173-7. PubMed ID: 7640422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.
    Gunnarsson B; Asaba H; Dawidson S; Wilhelmsson S; Bergström J
    Clin Nephrol; 1981 Mar; 15(3):135-42. PubMed ID: 7273488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of prescribed dialysis dose and survival in a cohort of chronic hemodialysis patients.
    Iseki K; Tozawa M; Takishita S
    Clin Exp Nephrol; 2003 Sep; 7(3):231-7. PubMed ID: 14586720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A kinetic model for heparin dosing in patients on chronic hemodialysis].
    González C; Vukusic A; Becerra P; Milosevic V; Orellana G; Saravia A
    Rev Med Chil; 1992 Aug; 120(8):905-9. PubMed ID: 1340966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of pentasaccharide in a dog model of hemodialysis.
    Hoppensteadt DA; Jeske WP; Walenga JM; Fu K; Yang LH; Ing T; Herbert JM; Fareed J
    Thromb Res; 1997 Oct; 88(2):159-70. PubMed ID: 9361369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hemodialysis without heparin. The effect on hemocoagulation parameters].
    Charvát J; Kaslíková J; Bláha J; Spánková H; Mlejnková M; Harosová H; Adamová Z
    Cas Lek Cesk; 1986 Dec; 125(49):1508-10. PubMed ID: 3802141
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-dose and heparin-free hemodialysis in children.
    Geary DF; Gajaria M; Fryer-Keene S; Willumsen J
    Pediatr Nephrol; 1991 Mar; 5(2):220-4. PubMed ID: 2031839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful use of a totally heparin grafted hemodialysis system in sheep.
    Schmer G; Teng LN; Cole JJ; Vizzo JE; Francisco MM; Scribner BH
    Trans Am Soc Artif Intern Organs; 1976; 22():654-63. PubMed ID: 951885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin pharmacokinetics during hemodialysis.
    Kandrotas RJ; Gal P; Douglas JB; Deterding J
    Ther Drug Monit; 1989 Nov; 11(6):674-9. PubMed ID: 2595748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.